Pfizer Inc. has been the center of several critical discussions amid its stock's performance dipping to 52-week lows and abandonment of its leading weight-loss drug development, Danuglipron. The discontinuation reportedly has limited impact on its valuation but was greeted with mixed responses amongst shareholders. Pfizer's decision has positioned rival obesity drug makers favorably in the market, with several making notable gains. Analysts like Jim Cramer have called the stock 'Dead Money' due to these developments.Despite the setbacks, some analysts believe the stock is undervalued and still a worthy high-yielding investment. It consistently ranks among the top dividend-paying stocks with a current yield close to 8%, making it appealing to income investors. The company has also received a CDC recommendation to expand the use of its ABRYSCO vaccine for RSV Prevention, which could offset some losses from its scrapped project. Despite a slump due to the weight-loss drug discontinuation, the company reaffirmed its 2025 guidance in line with expectations following solid Q4 earnings. The consensus on Wall Street remains mixed, with many questioning whether to buy, sell or hold the stock in the current market scenario.
Pfizer Stocks News Analytics from Wed, 04 Dec 2024 08:00:00 GMT to Fri, 18 Apr 2025 12:15:00 GMT -
Rating -4
- Innovation -6
- Information 5
- Rumor -2
